ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for ddt Track real-time Director Deals activity on the London Stock Exchange (LSE)

GSK Gsk Plc

1,402.50
-32.50 (-2.26%)
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -32.50 -2.26% 1,402.50 1,404.00 1,405.00 1,445.00 1,400.00 1,440.50 24,571,074 16:35:28
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 31.38B 2.58B 0.6287 22.32 58.77B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,435p. Over the last year, Gsk shares have traded in a share price range of 1,242.50p to 1,678.00p.

Gsk currently has 4,095,711,802 shares in issue. The market capitalisation of Gsk is £58.77 billion. Gsk has a price to earnings ratio (PE ratio) of 22.32.

Gsk Share Discussion Threads

Showing 34776 to 34796 of 34800 messages
Chat Pages: 1392  1391  1390  1389  1388  1387  1386  1385  1384  1383  1382  1381  Older
DateSubjectAuthorDiscuss
20/6/2025
21:30:51
Dope: "...Never change someone doing a good job because of short term stock undervaluation"

Short term? I've owned this crock for decades and it has been a serial bad performer. The only reason I'm showing a modest profit at all on my combined GSK/HLN holding is because the HLN allocation in the demerger has ben a star performer, up 54%. The new GSK element is up a mighty 0.2%!

I'm a long term hold income investor with a diversified port and GSK is in as my pharma sector rep. I don't concern myself much with share prices but mention the poor capital performance just out of interest, to dispel any beliefs that it is a good capital investment, at least on a lengthy hindsight view.

As for the future, who knows?

anhar
20/6/2025
17:48:03
Looks like I can add again in the 13s on what is a very high yield for a pharma stock
dope007
20/6/2025
16:36:15
Until the upside happens, keep taking dividends and buy more!
tradermichael
20/6/2025
15:29:42
Great post dope007!
indyavsukh
20/6/2025
13:34:30
She's doing a great job. Market will work it out eventually and these have 100% upside potential when they do. Never change someone doing a good job because of short term stock undervaluation
dope007
20/6/2025
12:45:24
Problem is, despite the good news updates of late, investors have no confidence in Emma-she lacks clout. What's she done on the US, for eg, to promote GSK.
cumnor
20/6/2025
10:32:57
GSK announced that Japan’s Ministry of Health, Labour and Welfare has accepted its application to expand the use of its RSV vaccine, Arexvy, to adults aged 18-49 at increased risk of severe RSV disease. This expansion, if approved, would make Arexvy the first vaccine available in Japan for this demographic, supported by positive Phase IIIb trial data. The move positions GSK as a leader in RSV prevention, with ongoing regulatory submissions in the US and Europe, potentially impacting its market presence and providing broader protection against RSV globally.
tradermichael
20/6/2025
09:51:50
If YOU'RE OVER-65...Some Alarming Stats (STAY WELL!)




In USA:


9/10 over 65 in US on 1 prescription at least.

40 - 45% of over 65 are on 5 or More

But let's not change the US health system but keep on doing what clearly hasnt been working for decades!!!

geckotheglorious
20/6/2025
09:21:15
Dooby
"FWIW I don't think this generalises to all vaccines"

Agreed.

This is why I have had all my vaccines over the years EXCEPT the Covid19 one.

For doing that I am a vax denier!!!

Which is clearly ridiculous.

geckotheglorious
19/6/2025
10:49:56
Japan Releases Bombshell Vax vs. Unvax Data on 18 Million People
The data speaks for itself—and the 3 to 4 month spike is impossible to ignore.

Japan Releases Bombshell Vax vs. Unvax Data on 18m people. Dr. Murakami’s conclusion was blunt: “the more doses you get, the sooner you’re likely to die, within a shorter period” Dr Murakami is the deputy director of RNA research at Tokyo University.

Dr. Yasufumi Murakami isn’t just some fringe voice. He’s a respected professor at the Tokyo University of Science, where he serves as vice director at the Research Center for RNA Science.

He holds a Doctor of Pharmaceutical Science from the University of Tokyo and has authored over 100 scientific publications.

Dr. Murakami’s conclusion was blunt: “…the more doses you get, the sooner you’re likely to die, within a shorter period…”

geckotheglorious
19/6/2025
09:16:43
GSK’s current expenditure in US manufacturing capabilities is close to $1.3bn.

I hope that Emma is focussing on publicity not just for new drugs and vaccines but also on investment for current and future manufacturing in the US.

tradermichael
19/6/2025
09:09:33
Just topped up again averaging down. Becoming a common theme here !
paulstills
19/6/2025
09:01:58
All this tarrif stuff and Trump saying they will move production here.From Google AI Glaxo already produce in the USA for the USA AI OverviewGlaxoSmithKline (GSK) has several manufacturing sites across the US, including locations in Pennsylvania, North Carolina, Maryland, and Montana. Specifically, they have facilities in Zebulon, North Carolina, and Upper Merion and Marietta, Pennsylvania. There is also a site in Hamilton, Montana, focused on vaccine production. Here's a more detailed breakdown:Pennsylvania: GSK has facilities in Upper Merion and Marietta, Pennsylvania. The Marietta site is undergoing a $800 million expansion to become a major vaccines and R&D hub. North Carolina: GSK has a significant presence in Zebulon, North Carolina, including a manufacturing and packaging plant. Maryland: GSK has a manufacturing site in Rockville, Maryland. Montana: The Hamilton, Montana, site is dedicated to vaccine manufacturing. Other Locations: GSK also has facilities in other locations, such as Rockville, Maryland.
dope007
18/6/2025
08:20:50
Back in here this morning.

Risky I know based on what Mr T is up to right now but it's a small start and I have no other direct sector exposure either.

Good luck all 👍🏻

tuftymatt
18/6/2025
08:15:22
The FDA currently lists 88 drugs as actively being in short supply in the US. Increasing tariffs on imported pharmaceuticals would critically impact access to medicines for millions of Americans.
tradermichael
16/6/2025
19:04:50
Yeah me too , been up and down more than bonnie blues knickers recently
alibizzle
16/6/2025
08:51:33
Hope so TM but just bought at 14.90 so apologies in advance to everyone
paulstills
16/6/2025
07:40:04
How long before 1550p is breached again with all the US madness?
tradermichael
13/6/2025
17:52:59
Yes short term you're right following with the wider market, except for oil and defence, but I'm looking at the longer term chart..
bountyhunter
13/6/2025
15:25:28
hTTps://www.independent.co.uk/bulletin/news/blenrep-myeloma-blood-cancer-treatment-nhs-b2769340.html
dplewis1
13/6/2025
15:02:25
TraderMichael
Post 34477

The future is here – and scientists at GSK are already using digital biological twins and organoids to create personalised solutions for patients with cancer.



Crispr the better bet surely for personalised solutions?

geckotheglorious
Chat Pages: 1392  1391  1390  1389  1388  1387  1386  1385  1384  1383  1382  1381  Older

Top Brokers in the UK

Spread Bet
CFD
Forex
Share

Your Recent History

Delayed Upgrade Clock